Compare TECH & ACHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TECH | ACHC |
|---|---|---|
| Founded | 1976 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 1.3B |
| IPO Year | 1989 | N/A |
| Metric | TECH | ACHC |
|---|---|---|
| Price | $58.84 | $14.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 13 |
| Target Price | ★ $71.23 | $24.00 |
| AVG Volume (30 Days) | 1.6M | ★ 3.4M |
| Earning Date | 02-04-2026 | 11-05-2025 |
| Dividend Yield | ★ 0.54% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.49 | ★ 1.18 |
| Revenue | $1,216,732,000.00 | ★ $3,265,548,000.00 |
| Revenue This Year | $2.33 | $6.50 |
| Revenue Next Year | $7.05 | $4.38 |
| P/E Ratio | $120.82 | ★ $12.03 |
| Revenue Growth | 3.85 | ★ 4.58 |
| 52 Week Low | $46.01 | $12.63 |
| 52 Week High | $79.28 | $47.08 |
| Indicator | TECH | ACHC |
|---|---|---|
| Relative Strength Index (RSI) | 45.70 | 38.70 |
| Support Level | $58.54 | $14.05 |
| Resistance Level | $59.64 | $14.74 |
| Average True Range (ATR) | 1.45 | 0.51 |
| MACD | 0.04 | 0.22 |
| Stochastic Oscillator | 49.84 | 48.86 |
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.